Literature DB >> 15767622

Recommendations for the diagnosis and treatment of the acute porphyrias.

Karl E Anderson1, Joseph R Bloomer, Herbert L Bonkovsky, James P Kushner, Claus A Pierach, Neville R Pimstone, Robert J Desnick.   

Abstract

The acute porphyrias, 4 inherited disorders of heme biosynthesis, cause life-threatening attacks of neurovisceral symptoms that mimic many other acute medical and psychiatric conditions. Lack of clinical recognition often delays effective treatment, and inappropriate diagnostic tests may lead to misdiagnosis and inappropriate treatment. We review the clinical manifestations, pathophysiology, and genetics of the acute porphyrias and provide recommendations for diagnosis and treatment on the basis of reviews of the literature and clinical experience. An acute porphyria should be considered in many patients with unexplained abdominal pain or other characteristic symptoms. The diagnosis can be rapidly confirmed by demonstration of a markedly increased urinary porphobilinogen level by using a single-void urine specimen. This specimen should also be saved for quantitative measurement of porphobilinogen, 5-aminolevulinic acid, and total porphyrin levels. Intravenous hemin therapy, started as soon as possible, is the most effective treatment. Intravenous glucose alone is appropriate only for mild attacks (mild pain, no paresis or hyponatremia) or until hemin is available. Precipitating factors should be eliminated, and appropriate supportive and symptomatic therapy should be initiated. Prompt diagnosis and treatment greatly improve prognosis and may prevent development of severe or chronic neuropathic symptoms. We recommend identification of at-risk relatives through enzymatic or gene studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767622     DOI: 10.7326/0003-4819-142-6-200503150-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  146 in total

1.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

2.  An atypical case of Guillain-Barré syndrome: acute intermittent porphyria.

Authors:  É Cuquemelle; S Ehrmann; K Razazi; J C Deybach; C Brun-Buisson; A W Thille
Journal:  Intensive Care Med       Date:  2012-01-25       Impact factor: 17.440

Review 3.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

Review 4.  [Diagnosis of the porphyrias : From A (as in aminolevulinic acid) to Z (as in zinc protoporphyrin)].

Authors:  V Kürten; N J Neumann; J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

5.  High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.

Authors:  Nicolas Pallet; Iadh Mami; Caroline Schmitt; Zoubida Karim; Arnaud François; Marion Rabant; Dominique Nochy; Laurent Gouya; Jean-Charles Deybach; Yichum Xu-Dubois; Eric Thervet; Hervé Puy; Alexandre Karras
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

6.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

7.  Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.

Authors:  Irene Paradisi; Sergio Arias
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

Review 8.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

9.  First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans.

Authors:  A E Bharucha; A Kulkarni; K M Choi; M Camilleri; M Lempke; G J Brunn; S J Gibbons; A R Zinsmeister; G Farrugia
Journal:  Clin Pharmacol Ther       Date:  2009-12-02       Impact factor: 6.875

10.  Heme status affects human hepatic messenger RNA and microRNA expression.

Authors:  Herbert L Bonkovsky; Weihong Hou; Nury Steuerwald; Qing Tian; Ting Li; Judy Parsons; Alicia Hamilton; Sunil Hwang; Laura Schrum
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.